

- ethanol poisoning. *Int J Artif Organs* 1999;1:18-20.
3. Kraut J, Kurtz I. Toxic alcohol ingestions: clinical features, diagnosis, and management. *Clin J Am Soc Nephrol* 2008;3:208-25.
 4. Adinoff B, Bone H, Linnoila M. Acute ethanol poisoning and the ethanol withdrawal syndrome. *Medical Toxicology* 1988;3:172-93.

J.O. Quispe Gonzales, B. Gómez Giralda, C. Ruiz-Zorrilla López, M.I. Acosta Ochoa, K. Ampuero Anachuri, A. Molina Miguel

Nephrology Department. Río Hortega University Hospital. Valladolid, Spain

Correspondencia: C. Ruiz-Zorrilla López
Sección de Nefrología.

Hospital Universitario Río Hortega.
Dulzaina, 2. 47012 Valladolid.
carlosruizzorrilla@hotmail.com

Delayed diagnosis of primary hyperoxaluria in a young patient with advanced chronic renal failure

Nefrología 2011;31(2):227-9

doi:10.3265/Nefrología.pre2010.Nov.10725

To the Editor,

Primary hyperoxaluria (PHO) is a fairly rare metabolic alteration. Its annual incidence is 0.11-0.26/100 000 births and its prevalence is 1-2.9/1000 000 inhabitants, approximately.¹ In Spain, there is a relatively high number of cases, given its increased incidence on the Canary Islands (especially La Gomera).² Diagnosis is usually delayed: with an average interval of 3.4 years between the onset of the symptoms and its diagnosis. Only 30% of cases are diagnosed early.³ As such, in most cases, patients present with oxalate deposits in the definitive diagnosis, even in the cardiovascular system, which inevitably leads to death. PHO is caused by an enzymatic

defect located in the hepatocyte peroxisome, which enhances glyoxylate conversion to poorly soluble oxalate.⁴ The *AGXT* gene is affected in primary hyperoxaluria type I, which is found in the chromosome 2q36-37. It corresponds with the alanine-glyoxylate aminotransferase enzyme (43kDa protein)², which needs vitamin B₆ (pyridoxine) to function correctly. Various mutations in the *AGXT* gene have been observed, involving multiple defects, among which the most frequent is the lack of immunoreactive and catalytic activity (42%).⁵ The only treatment performed successfully in these patients is liver or liver and kidney transplant, which may supplement enzymatic activity and kidney function, respectively.

We present the case of a 24-year-old Maghreb man, with a history of chronic renal failure (CRF) secondary to nephrocalcinosis. He presented with several infections, two abscesses in the right psoas muscle and the left sternoclavicular joint, although the aetiological origin could not be identified in either of the two cases. In the same year he had a thalamic stroke and right perimesencephalic haemorrhage. He was admitted to his area hospital with severely deteriorated condition, with recurrent fever and episodes of arthritis in his right shoulder due to *S. epidermis* and in his left sternoclavicular joint due to enterococcus. Both were secondary to permanent catheter-related bacteraemia in the right jugular vein (he previously presented with thrombosis in several vascular accesses). During hospital stay (which lasted a year) numerous complications occurred: chronic severe anaemia, upper digestive haemorrhage, uraemic pericarditis, and pneumonia with pleural effusion. In the last few weeks of the hospital stay, he had left-side neck pains, significantly limited functions, fasciculations, fever, and negative blood culture tests. Magnetic resonance imaging (Figure 1) was performed. Secondary spondylodiscitis was suspected and the patient was referred to our health centre for a decompressive laminectomy.

During the physical examination upon arrival, we found deterioration of his general condition, cachexia with muscular atrophy (which prevented him from walking), hypotension, tachycardia and fever. He had a normal heart rate and a pansystolic murmur with hypoventilation of the lung bases. He had painless hepatosplenomegaly. Both knees were swollen and the right shoulder was visibly swollen.

Anaemia was discovered in the laboratory tests (Hb: 8.3g/dl), leukocytosis: 18 900, parathyroid hormone (PTH): 83pg/ml and changes to inflammatory and nutritional parameters (GGT: 544IU/l; albumin: 0.7g/dl and ferritin: 5.93ng/ml PCR). A bone scan was performed, which showed signs of advanced secondary hyperthyroidism. The main alterations can be seen in Figure 1. The cervical CT revealed a significant kyphosis at the C5-C6 vertebral body height, alteration in their morphology and a severe reduction in the antero-posterior diameter, which significantly compressed the medulla at that point and caused foraminal stenosis.

A biopsy and a bone marrow aspiration were performed which found multinucleated giant cells derived from monocyte macrophages containing oxalate crystals birefringent to polarised light. In the bone marrow the medullar space had been substituted by concentrically disposed crystals, grouped together in a star or rosette shape, which were refringent to polarised light, with peripheral reaction of giant cells and trabecular bone destruction (Figure 2). With these findings the patient was diagnosed with primary hyperoxaluria. Palliative treatment with vitamin B and intensive dialysis was indicated, but the patient died 30 days after hospitalisation.

This case illustrates the harmful consequences associated with the delayed diagnosis of this rare disease, which is fatal if aggressive treatment is not indicated early. Current therapeutic alternatives for patients with CRF are

palliative (kidney transplant) or curative, although they have a high morbidity rate (liver and kidney transplant).²

In 1997, Hoppe found a very low PHO frequency in the dialysis population. He observed delayed diagnosis in 42% of the patients and 30% were diagnosed when they already had end-stage kidney disease.³

The most common and earliest manifestations of the disease are nephrocalcinosis (due to oxalate crystals forming in the kidney parenchyma) and urolithiasis (being excreted through the pyelocaliceal system). Manifestations vary depending on the patient's age. In small children, it is characterised by CRF with massive parenchymal oxalosis. Older children present with symptoms of urolithiasis and in some cases, complete obstruction with acute renal failure. It often occurs with end-stage kidney disease in adult patients.⁶ Unfortunately, PHO diagnosis was delayed for our patient, leading to his death.

A simple method for detecting this disease can be measuring urinary oxalate excretion. In normal conditions, excretion is 0.5mmol/1.73m²/day or 45mg/1.73m²/day. People with PHO have a significant increase in urinary oxalate excretion (>1mmol/1.73m²/day or 90mg/1.73m²/day).⁶ This excretion rate is less useful for kidney failure patients, as in our case, given that the patient already had advanced CRF. In these cases, the increase in plasma oxalate would help to reach a diagnosis, alongside calcium oxalate in tissues,⁷ although not all laboratories have this possibility. A liver biopsy is the only test which confirms definitive diagnosis of PHO. Depending on the laboratory, it can provide information on whether there is immunoreactive protein or not (Western blot), subcellular localisation (IF) and even the type of mutation (sequencing).⁹




Figure 1.

In our case, diagnosis was performed by biopsy and bone marrow aspiration. As a general rule, oxalate deposits appear in end-stage kidney failure, developing more quickly during chronic haemodialysis. These

oxalate deposits with surrounding reaction provoke lesions similar to secondary hyperparathyroidism⁸ and severe anaemia resistant to erythropoietin (EPO), as has been described previously.¹⁰




Figure 2. Multinucleated giant cells with oxalate crystals (panels A and B). Oxalate crystals birefringent to polarised light (panel C). Star or rosette-shaped oxalate crystal deposits (panel D), Refringent to polarised light (panel E). Peripheral reaction and destruction of bone trabeculae (panel F).

Lastly, we must stress the importance of detecting this disease early, given that the effectiveness of treatment depends on how quickly it is diagnosed. A delayed diagnosis leads to CRF and massive oxalate deposits in organs and tissues. This must be considered for the population at risk: i.e. people from the Canary Islands and Maghrebians. The Canarian population with PHO are not Maghreb but Caucasian, but given that it is an island, a cross over has occurred.

1. Levy M, Feingold J. Estimating prevalence in single gene kidney diseases progressing to renal failure. *Kidney Int* 2000;58:925.
2. Santana A, Torres A, Salido E. Patología molecular de la hiperoxaluria primaria. *Nefrología* 2003;23(Supl 1):90.
3. Hoppe B, Langman CB. A United States Surrey on diagnosis, treatment, and outcome of primary hyperoxaluria. *Pediatr Nephrol* 2003;18:986.
4. Danpure CJ. Metabolic and clinical heterogeneity of primary hyperoxaluria type I. *Am J Kidney Dis* 1991;17:366.
5. Danpure CJ. Advances in the enzymology and molecular genetics of primary hyperoxaluria type 1. Prospects for gene therapy. *Nephrol Dial Trasplant* 1995;10(Suppl 8):24.
6. Hoppe B, Leumann E. Diagnostic and therapeutic strategies in hyperoxaluria: a plea for early intervention. *Nephrol Dial Trasplant* 2004;19:39.
7. Hoppe B, Kemper MJ, et al. et al. Plasmacalcium-oxalate saturation in children with renal insufficiency and in children with primary hyperoxaluria. *Kidney Intern* 1998;54:921.
8. Lorenzo V, Torres A, Hernandez D, et al. Evolución de la enfermedad ósea en pacientes con hiperoxaluria primaria en hemodiálisis. *Nefrología* 1990;10(1):53.
9. Lorenzo V, Álvarez, A, Torres A, et al. Presentation and role of transplantation in adult patients with type 1 primary hyperoxaluria and the I244T AGXT mutation: Single-center experience. *Kidney Int* 2006;1115-9.
10. Lorenzo V, Hernández D, Domínguez M, et al. Oxalosis as a cause of absolute resistance to EPO in chronic hemodialysis patients. *Nephrol Dial Trasplant* 1992;7:1163-4.

M. Martín¹, G. Martín Reyes¹, A. Torres de Rueda¹, R. Toledo Rojas¹, C. Jironda¹, I. García², T. García de la Oliva³, M.L. Pérez Vaca⁴, D. Hernández¹

¹ Nephrology Department. Carlos Haya Hospital. Málaga, Spain.

² Anatomical Pathology Department. Carlos Haya Hospital. Málaga, Spain.

³ Radiology Department. Carlos Haya Hospital. Málaga, Spain.

⁴ Haematology Department. Carlos Haya Hospital. Málaga, Spain.

Correspondence: G. Martín Reyes

Servicio de Nefrología.

Hospital Regional Universitario Carlos Haya.

Almirante Enríquez 10, Bajo D. 29017 Málaga.

Spain.

gmartinr@senefro.org

Diagnosis of secondary hypertension causing miscarriage during the first trimester of pregnancy

Nefrología 2011;31(2):229-31

doi:10.3265/Nefrologia.pre2010.Dec.10677

To the Editor,

Uncontrolled arterial hypertension (AHT) during pregnancy compromises correct gestation development. We describe the case of a 41-year-old pregnant woman who was referred to our unit after having suffered a miscarriage in the tenth week of gestation.

The patient had no personal or family history of interest, and ATH was detected in the eighth week of pregnancy. She visited the emergency department on several occasions due to metrorrhagia and asthenia, with blood pressure (BP) at around 160-170/100-110mm Hg. Alpha-methyldopa was prescribed at 500mg every 8 hours, gradually increasing doses but without adequately controlling AHT. In the tenth week of pregnancy, the patient had a miscarriage and was referred to

the outpatient nephrology unit.

In the physical examination BP was 162/100mm Hg and heart rate (HR) 74 systoles. She had no distal oedemas or other data of interest.

Supplementary tests

1. Haemogram: normal.
2. Biochemistry: creatinine: 0.92mg/dl; glomerular filtration rate (GFR) calculated using MDRD-4 equation: 67ml/min; sodium: 140mEq/l; potassium: 3.3mEq/l; calcium: 9.7mg/dl; uric acid: 4.7mg/dl; GOT: 26IU/dl; GPT: 21IU/dl; LDH: 337IU/l; total bilirubin: 0.3mg/dl; normal coagulation, negative indirect Coombs test.
3. Venous gasometry: normal.
4. Urine: negative systematic and sedimentary tests, microalbuminuria/creatinine index: 8µg/mg; uricosuria: 0.3g/24h.
5. Chest X-ray: no pathological findings.
6. Electrocardiogram: sinus rhythm, no blockages or signs of ischaemia.
7. Funduscopy: normal.
8. Anatomopathological exam of the placenta: normal.

The abdominal ultrasound and renal Doppler scan were normal. Drug treatment was started with calcium antagonists and doxazosin, achieving better pressure control, although it was insufficient. A second analysis found plasma aldosterone of 1161pg/ml and urinary aldosterone of 22.68µg/24h, with a plasma renin activity at baseline of 0.6ng/ml/h and aldosterone/renin rate of 193.3. The remaining parameters (catecholamines in urine, thyroid hormones and plasma cortisol) were all normal. Given the suspected primary hyperaldosteronism (PHA), a saline overload test was performed and 2 litres of physiological saline solution administered over 4 hours. Previous treatment did not have to be modified, however, we do recommend suspending angiotensin-converting enzymes (ACE), angiotensin II receptor antagonists (ARA-II), beta-blockers